Reuters: Health
Biogen Inc revealed surprise plans to seek U.S. regulatory approval for its Alzheimer's treatment aducanumab on Tuesday, saying new analysis of clinical trials showed promise, just months after it had shelved two studies.
Biogen resurrects Alzheimer's drug; shares jump 35%
Biogen resurrects Alzheimer's drug; shares jump 35%
Reuters: Health
Biogen Inc revealed surprise plans to seek U.S. regulatory approval for its Alzheimer's treatment aducanumab on Tuesday, saying new analysis of clinical trials showed promise, just months after it had shelved two studies.
Reuters: Health
Biogen Inc revealed surprise plans to seek U.S. regulatory approval for its Alzheimer's treatment aducanumab on Tuesday, saying new analysis of clinical trials showed promise, just months after it had shelved two studies.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment